Tuberculosis even more drug resistant

Research output: Contribution to journalArticle

Abstract

A recent survey made by the World Health Organization and the U.S. Centers for Disease Control and Prevention, nearly 1 in 30 human cases of tuberculosis (TB) is now more resistant to both primary nad secondary antibiotic treatments. The survey reports that the prevalence of "multiple-drug resistant" TB strains, which can survive the first two antibiotics typically used rose from 29 to 39 percent between 2000 and 2004. The use of streptomycin and other antibiotics made the disease highly treatable but due to misuse of these drugs has allowed resistant strains to flourish. Pharmaceutical companies and nonprofit initiatives speeds up their R&D efforts in response to this rising of TB resistance. Still, the key is to ensure that patients complete the full course of treatment to prevent such TB resistance.

Original languageEnglish
Pages (from-to)8
Number of pages1
JournalWorld Watch
Volume19
Issue number4
Publication statusPublished - Jul 2006

Fingerprint

tuberculosis
contagious disease
drug
antibiotics
Disease
disease control
World Health Organization
WHO
pharmaceutical

ASJC Scopus subject areas

  • Geography, Planning and Development

Cite this

Tuberculosis even more drug resistant. / Stair, Peter C.

In: World Watch, Vol. 19, No. 4, 07.2006, p. 8.

Research output: Contribution to journalArticle

@article{5b6d60cf8ef742bd9007d006200686a3,
title = "Tuberculosis even more drug resistant",
abstract = "A recent survey made by the World Health Organization and the U.S. Centers for Disease Control and Prevention, nearly 1 in 30 human cases of tuberculosis (TB) is now more resistant to both primary nad secondary antibiotic treatments. The survey reports that the prevalence of {"}multiple-drug resistant{"} TB strains, which can survive the first two antibiotics typically used rose from 29 to 39 percent between 2000 and 2004. The use of streptomycin and other antibiotics made the disease highly treatable but due to misuse of these drugs has allowed resistant strains to flourish. Pharmaceutical companies and nonprofit initiatives speeds up their R&D efforts in response to this rising of TB resistance. Still, the key is to ensure that patients complete the full course of treatment to prevent such TB resistance.",
author = "Stair, {Peter C}",
year = "2006",
month = "7",
language = "English",
volume = "19",
pages = "8",
journal = "World Watch",
issn = "0896-0615",
publisher = "Worldwatch Institute",
number = "4",

}

TY - JOUR

T1 - Tuberculosis even more drug resistant

AU - Stair, Peter C

PY - 2006/7

Y1 - 2006/7

N2 - A recent survey made by the World Health Organization and the U.S. Centers for Disease Control and Prevention, nearly 1 in 30 human cases of tuberculosis (TB) is now more resistant to both primary nad secondary antibiotic treatments. The survey reports that the prevalence of "multiple-drug resistant" TB strains, which can survive the first two antibiotics typically used rose from 29 to 39 percent between 2000 and 2004. The use of streptomycin and other antibiotics made the disease highly treatable but due to misuse of these drugs has allowed resistant strains to flourish. Pharmaceutical companies and nonprofit initiatives speeds up their R&D efforts in response to this rising of TB resistance. Still, the key is to ensure that patients complete the full course of treatment to prevent such TB resistance.

AB - A recent survey made by the World Health Organization and the U.S. Centers for Disease Control and Prevention, nearly 1 in 30 human cases of tuberculosis (TB) is now more resistant to both primary nad secondary antibiotic treatments. The survey reports that the prevalence of "multiple-drug resistant" TB strains, which can survive the first two antibiotics typically used rose from 29 to 39 percent between 2000 and 2004. The use of streptomycin and other antibiotics made the disease highly treatable but due to misuse of these drugs has allowed resistant strains to flourish. Pharmaceutical companies and nonprofit initiatives speeds up their R&D efforts in response to this rising of TB resistance. Still, the key is to ensure that patients complete the full course of treatment to prevent such TB resistance.

UR - http://www.scopus.com/inward/record.url?scp=33745712656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745712656&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 8

JO - World Watch

JF - World Watch

SN - 0896-0615

IS - 4

ER -